Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice
An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of...
Gespeichert in:
Veröffentlicht in: | Biological & pharmaceutical bulletin 2000/04/01, Vol.23(4), pp.432-437 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 437 |
---|---|
container_issue | 4 |
container_start_page | 432 |
container_title | Biological & pharmaceutical bulletin |
container_volume | 23 |
creator | MIYAKE, Isao NABE, Takeshi YAMAMURA, Hideki KOHNO, Shigekatsu |
description | An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs. |
doi_str_mv | 10.1248/bpb.23.432 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71072892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120456541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-4b1ba331b66100e6c7635fa80a876505a06d5cbbada9c175b5d02a8c5cff092f3</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS1ERbeFCx8AWQL1gJTFfxPnuKwKVGqFBOVsjR2n9SrrBNs5lE-Pl6xK1Ystzfw8z_MeQm8pWVMm1CczmTXja8HZC7SiXDSVZFS-RCvSUlXVVKpTdJbSjhDSEMZfoVNKGiUEYys0_nBTHLvZejM4_NlP95C8xds5Q3DjnPBl5_aAr0JBXIfNA74dJ29hwBA6XB47yKW-maahVLMfAx57vAnZ37mAfcA_XUg--z8FuvHWvUYnPQzJvTne5-jXl8vb7bfq-vvXq-3murJSNbkShhrgnJq6poS42jY1lz0oAqqpJZFA6k5aY6CD1tJGGtkRBspK2_ekZT0_RxfL3LLd79mlrPc-WTcMy1q6KRYw1bICvn8G7sY5hvI3TYUoBjZMHKiPC2XjmFJ0vZ6i30N80JToQwi6hKAZ1yWEAr87jpzN3nVP0MX1Anw4ApCKlX2EYH36z3EpqZAF2y7YLmW4c499iNnbwR0kadvyf7LLUdQfu_YeonaB_wXC0qZr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449187242</pqid></control><display><type>article</type><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</creator><creatorcontrib>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</creatorcontrib><description>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.23.432</identifier><identifier>PMID: 10784422</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>allergic dermatitis ; Allergic diseases ; Animals ; Antigens - administration & dosage ; Benzoquinones - therapeutic use ; Biological and medical sciences ; Cyclooxygenase Inhibitors - therapeutic use ; Dermatitis, Allergic Contact - drug therapy ; Dermatitis, Allergic Contact - etiology ; histamine ; Histamine and antagonists. Allergy ; Histamine H1 Antagonists - therapeutic use ; IgE ; Immunopathology ; Indomethacin - therapeutic use ; Lipoxygenase Inhibitors - therapeutic use ; Male ; Medical sciences ; Mice ; Ovalbumin - administration & dosage ; paw edema ; Pharmacology. Drug treatments ; Pyrilamine - therapeutic use ; Reproducibility of Results ; Skin allergic diseases. Stinging insect allergies</subject><ispartof>Biological and Pharmaceutical Bulletin, 2000/04/01, Vol.23(4), pp.432-437</ispartof><rights>The Pharmaceutical Society of Japan</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1355145$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10784422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MIYAKE, Isao</creatorcontrib><creatorcontrib>NABE, Takeshi</creatorcontrib><creatorcontrib>YAMAMURA, Hideki</creatorcontrib><creatorcontrib>KOHNO, Shigekatsu</creatorcontrib><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</description><subject>allergic dermatitis</subject><subject>Allergic diseases</subject><subject>Animals</subject><subject>Antigens - administration & dosage</subject><subject>Benzoquinones - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Dermatitis, Allergic Contact - drug therapy</subject><subject>Dermatitis, Allergic Contact - etiology</subject><subject>histamine</subject><subject>Histamine and antagonists. Allergy</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>IgE</subject><subject>Immunopathology</subject><subject>Indomethacin - therapeutic use</subject><subject>Lipoxygenase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Ovalbumin - administration & dosage</subject><subject>paw edema</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrilamine - therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9v1DAQxS1ERbeFCx8AWQL1gJTFfxPnuKwKVGqFBOVsjR2n9SrrBNs5lE-Pl6xK1Ystzfw8z_MeQm8pWVMm1CczmTXja8HZC7SiXDSVZFS-RCvSUlXVVKpTdJbSjhDSEMZfoVNKGiUEYys0_nBTHLvZejM4_NlP95C8xds5Q3DjnPBl5_aAr0JBXIfNA74dJ29hwBA6XB47yKW-maahVLMfAx57vAnZ37mAfcA_XUg--z8FuvHWvUYnPQzJvTne5-jXl8vb7bfq-vvXq-3murJSNbkShhrgnJq6poS42jY1lz0oAqqpJZFA6k5aY6CD1tJGGtkRBspK2_ekZT0_RxfL3LLd79mlrPc-WTcMy1q6KRYw1bICvn8G7sY5hvI3TYUoBjZMHKiPC2XjmFJ0vZ6i30N80JToQwi6hKAZ1yWEAr87jpzN3nVP0MX1Anw4ApCKlX2EYH36z3EpqZAF2y7YLmW4c499iNnbwR0kadvyf7LLUdQfu_YeonaB_wXC0qZr</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>MIYAKE, Isao</creator><creator>NABE, Takeshi</creator><creator>YAMAMURA, Hideki</creator><creator>KOHNO, Shigekatsu</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20000401</creationdate><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><author>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-4b1ba331b66100e6c7635fa80a876505a06d5cbbada9c175b5d02a8c5cff092f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>allergic dermatitis</topic><topic>Allergic diseases</topic><topic>Animals</topic><topic>Antigens - administration & dosage</topic><topic>Benzoquinones - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Dermatitis, Allergic Contact - drug therapy</topic><topic>Dermatitis, Allergic Contact - etiology</topic><topic>histamine</topic><topic>Histamine and antagonists. Allergy</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>IgE</topic><topic>Immunopathology</topic><topic>Indomethacin - therapeutic use</topic><topic>Lipoxygenase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Ovalbumin - administration & dosage</topic><topic>paw edema</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrilamine - therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIYAKE, Isao</creatorcontrib><creatorcontrib>NABE, Takeshi</creatorcontrib><creatorcontrib>YAMAMURA, Hideki</creatorcontrib><creatorcontrib>KOHNO, Shigekatsu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIYAKE, Isao</au><au>NABE, Takeshi</au><au>YAMAMURA, Hideki</au><au>KOHNO, Shigekatsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>23</volume><issue>4</issue><spage>432</spage><epage>437</epage><pages>432-437</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>10784422</pmid><doi>10.1248/bpb.23.432</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-6158 |
ispartof | Biological and Pharmaceutical Bulletin, 2000/04/01, Vol.23(4), pp.432-437 |
issn | 0918-6158 1347-5215 |
language | eng |
recordid | cdi_proquest_miscellaneous_71072892 |
source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
subjects | allergic dermatitis Allergic diseases Animals Antigens - administration & dosage Benzoquinones - therapeutic use Biological and medical sciences Cyclooxygenase Inhibitors - therapeutic use Dermatitis, Allergic Contact - drug therapy Dermatitis, Allergic Contact - etiology histamine Histamine and antagonists. Allergy Histamine H1 Antagonists - therapeutic use IgE Immunopathology Indomethacin - therapeutic use Lipoxygenase Inhibitors - therapeutic use Male Medical sciences Mice Ovalbumin - administration & dosage paw edema Pharmacology. Drug treatments Pyrilamine - therapeutic use Reproducibility of Results Skin allergic diseases. Stinging insect allergies |
title | Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reproducible%20Biphasic%20Cutaneous%20Edema%20Induced%20by%20Topical%20and%20Repeated%20Application%20of%20Antigen%20in%20Sensitized%20Mice&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=MIYAKE,%20Isao&rft.date=2000-04-01&rft.volume=23&rft.issue=4&rft.spage=432&rft.epage=437&rft.pages=432-437&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.23.432&rft_dat=%3Cproquest_cross%3E3120456541%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449187242&rft_id=info:pmid/10784422&rfr_iscdi=true |